Christopher Potts

Christopher Potts is the Co-Founder and CEO of Monarch Therapeutics, Inc., initiating a cell therapy biotech aimed at treating solid tumors since November 2023. Previously, as Global Head of Intellectual Property at Legend Biotech, Christopher led a multi-national team to optimize corporate IP structure and deliver key assets. At Lonza, Christopher held multiple roles, including Head of IP for both the Biologics and Cell & Gene Divisions, driving IP strategy and overseeing a team of attorneys in support of various business units. Early career experience includes positions at Cantor Colburn LLP and Nutter McClennen & Fish LLP, concentrating on patent law and litigation, alongside engineering roles at General Electric, Cargill, and EnteraTech, Inc. Christopher Potts earned a B.S. in Chemical and Biomolecular Engineering from The Ohio State University, a J.D. with honors from the University of Connecticut School of Law, and a Management Development Certificate from The Johns Hopkins University Carey Business School.